Global News

Symbiomix completes SYM-1219 enrollment

Monday, August 31, 2015

Symbiomix has completed patient enrollment in a phase III clinical study, the second pivotal trial of SYM-1219, a single-dose, oral product candidate for the treatment of bacterial vaginosis (BV). Earlier this year Symbiomix announced positive results from the first pivotal trial for SYM-1219. Symbiomix expects to finish the second pivotal trial by the end of 2015, which would enable an NDA filing with the FDA in mid-2016.

[Read More]

tranSMART platform named award finalist

Monday, August 31, 2015

The tranSMART Foundation, a nonprofit organization providing a global, open-source knowledge management platform for scientists to share pre-competitive translational research data, has announced its tranSMART v1.2 platform has been selected as a 2015 R&D 100 Award Finalist by R&D Magazine in the Software/Services category. The R&D 100 Award recognizes the 100 most technologically significant products introduced in the past year.

[Read More]